Xenetic Biosciences (XBIO)
NASDAQ:XBIO
XBIO Stock Chart & Stats
$2.21
-$0.03(-0.75%)
At close: 4:00 PM EST
$2.21
-$0.03(-0.75%)
Day’s Range― - ―
52-Week Range$1.90 - $13.93
Previous CloseN/A
Volume4.73K
Average Volume (3M)1.70M
Market Cap
$6.23M
Enterprise Value-$3.25M
Total Cash (Recent Filing)$7.88M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.17
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding2,291,056
10 Day Avg. Volume5,053,508
30 Day Avg. Volume1,695,238
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.50
Price to Sales (P/S)1.24
P/FCF Ratio-1.61
Enterprise Value/Market Cap-0.52
Enterprise Value/Revenue-1.09
Enterprise Value/Gross Profit-1.09
Enterprise Value/Ebitda1.16
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-light Balance SheetA nearly debt-free capital structure materially reduces refinancing and interest-rate risk over the medium term. This durability preserves optionality to fund R&D or partnerships via equity or non-debt instruments and lowers fixed financial obligations that can strain early-stage biotech cash flow.
Improving Revenue MomentumRe-acceleration of revenue in 2025 signals strengthening top-line traction versus recent years, suggesting improving product or collaboration uptake. A sustained revenue trend supports longer-term operational scaling and can reduce reliance on financing if continued across upcoming reporting periods.
Lean Operating StructureA very small headcount implies low fixed payroll and overhead, allowing management to allocate capital flexibly to outsourced R&D and milestone-driven investments. This lean model can extend runway per financing and supports nimble strategic pivots common in early-stage biotech.
Bears Say
Persistent Negative Cash FlowChronic negative operating and free cash flow indicate structural cash burn tied to R&D and operations. Over 2–6 months this sustains dependency on external capital, increasing dilution risk and constraining long-term planning unless demonstrable revenue or financing sources materialize.
Ongoing Net Losses And Thin MarginsLarge, persistent net losses and very negative margins show the business has not reached operating scale. Sustained negative profitability erodes equity and limits internal cash generation, forcing reliance on external funding and raising execution risk for achieving commercial sustainability.
Governance / Shareholder Engagement RiskRepeated adjournments for lack of quorum point to weak shareholder engagement and governance friction. This can delay strategic decisions, complicate financing or partnership approvals, and undermine investor confidence—an enduring operational and executional risk for corporate actions.
Xenetic Biosciences News
XBIO FAQ
What was Xenetic Biosciences’s price range in the past 12 months?
Xenetic Biosciences lowest stock price was $1.90 and its highest was $13.93 in the past 12 months.
What is Xenetic Biosciences’s market cap?
Xenetic Biosciences’s market cap is $6.23M.
When is Xenetic Biosciences’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Xenetic Biosciences’s earnings last quarter?
Currently, no data Available
Is Xenetic Biosciences overvalued?
According to Wall Street analysts Xenetic Biosciences’s price is currently Overvalued.
Does Xenetic Biosciences pay dividends?
Xenetic Biosciences does not currently pay dividends.
What is Xenetic Biosciences’s EPS estimate?
Xenetic Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Xenetic Biosciences have?
Xenetic Biosciences has 2,291,056 shares outstanding.
What happened to Xenetic Biosciences’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Xenetic Biosciences?
Currently, no hedge funds are holding shares in XBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Xenetic Biosciences
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
Technical Analysis
Ownership Overview
―
Insiders
0.74% Mutual Funds
0.72% Other Institutional Investors
98.24% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---